van den Brandt P, Ziegler R, Wang M, Hou T, Li R, Adami H
Eur J Epidemiol. 2020; 36(1):37-55.
PMID: 33128203
PMC: 7847460.
DOI: 10.1007/s10654-020-00688-3.
Calaf G, Ponce-Cusi R, Aguayo F, Munoz J, Bleak T
Oncol Lett. 2020; 20(1):19-32.
PMID: 32565930
PMC: 7286136.
DOI: 10.3892/ol.2020.11566.
Shawon M, Eriksson M, Li J
Breast Cancer Res. 2017; 19(1):84.
PMID: 28732505
PMC: 5521119.
DOI: 10.1186/s13058-017-0875-9.
Bertrand K, Baer H, Orav E, Klifa C, Shepherd J, Van Horn L
Breast Cancer Res. 2015; 17:95.
PMID: 26174168
PMC: 4502611.
DOI: 10.1186/s13058-015-0601-4.
MacLennan M, Ma D
Breast Cancer Res. 2010; 12(5):211.
PMID: 21067551
PMC: 3096965.
DOI: 10.1186/bcr2646.
Body fatness at young ages and risk of breast cancer throughout life.
Baer H, Tworoger S, Hankinson S, Willett W
Am J Epidemiol. 2010; 171(11):1183-94.
PMID: 20460303
PMC: 2915489.
DOI: 10.1093/aje/kwq045.
Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study.
Baer H, Colditz G, Rosner B, Michels K, Rich-Edwards J, Hunter D
Breast Cancer Res. 2005; 7(3):R314-25.
PMID: 15987426
PMC: 1143575.
DOI: 10.1186/bcr998.
Timing of exposure and mammary cancer risk.
Lamartiniere C
J Mammary Gland Biol Neoplasia. 2002; 7(1):67-76.
PMID: 12160087
DOI: 10.1023/a:1015722507237.
Tallness and overweight during childhood have opposing effects on breast cancer risk.
Hilakivi-Clarke L, Forsen T, Eriksson J, Luoto R, Tuomilehto J, Osmond C
Br J Cancer. 2001; 85(11):1680-4.
PMID: 11742488
PMC: 2363976.
DOI: 10.1054/bjoc.2001.2109.
Genistein: does it prevent or promote breast cancer?.
Bouker K, Hilakivi-Clarke L
Environ Health Perspect. 2000; 108(8):701-8.
PMID: 10964789
PMC: 1638285.
DOI: 10.1289/ehp.00108701.
Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis.
Hilakivi-Clarke L, Onojafe I, Raygada M, Cho E, Skaar T, Russo I
Br J Cancer. 1999; 80(11):1682-8.
PMID: 10468283
PMC: 2363126.
DOI: 10.1038/sj.bjc.6690584.
Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat.
Brown N, Lamartiniere C
Environ Health Perspect. 1995; 103(7-8):708-13.
PMID: 7588483
PMC: 1522196.
DOI: 10.1289/ehp.95103708.
The effects of neonatal androgenization on mammary gland mitotic rate and susceptibility of carcinogen-induced mammary dysplastigenesis and tumorigenesis in LEW/Mai rats.
Purnell D
Am J Pathol. 1980; 99(2):463-74.
PMID: 6769336
PMC: 1903501.
Stimulation by neonatal treatment with vitamin A of spontaneous mammary tumor development in GRS/A mice.
Nagasawa H
Breast Cancer Res Treat. 1984; 4(3):205-8.
PMID: 6487822
DOI: 10.1007/BF01806486.
Plasma hormone levels and the incidence of carcinogen-induced mammary tumours in two strains of rat.
Hawkins R, Drewitt D, Freedman B, Killin E, Jenner D, Cameron E
Br J Cancer. 1976; 34(5):546-9.
PMID: 826265
PMC: 2025204.
DOI: 10.1038/bjc.1976.209.
The influence of prenatal or neonatal administration of 2-bromo-alpha-ergocryptine on pituitary prolactin secretion and normal and neoplastic mammary growth in adult mice.
Nagasawa H, Yanai R
J Endocrinol Invest. 1978; 1(3):273-6.
PMID: 583157
DOI: 10.1007/BF03350393.
